Amneal Pharma <AMRX.O>: JPMorgan resumes coverage with Overweight rating; target price $22
AMRX•Related News
BioArctic Q2 FY26 turns to net loss of SEK 11.2 million; revenue falls to SEK 247.5 million
LLY•
Press Digest - Wall Street Journal - August 26
SPY•
US Cash Crude-Grades mixed on final day of cash roll period
XOM•
Scotiabank: National Bank of Canada raises to outperform from sector perform; raises target price to C$142 from C$128
BNS•
DICK'S Sporting Goods, Inc. <DKS.N>: D.A. Davidson cuts target price to $205 from $260
DKS•